3TC: Lamivudine; ABC: Abacavir; DRV: Darunavir; DTG: Dolutegravir; EFV: Efavirenz; FTC: Emtricitabine; rtv: Ritonavir; TDF: Tenofovir. Enfuvirtide No interaction ...
The majority (83%) received protease inhibitors in combination with tenofovir; specifically, 74% received ritonavir-boosted protease inhibition. Didanosine was the most commonly (43%) prescribed ...
The third pivotal study in treatment-naive patients compared dolutegravir to the DHHS guideline recommended boosted protease inhibitor darunavir/ritonavir. The FLAMINGO study is a 96-week ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback